Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
64Cu-NODAGA-ZHER2:S1
- Development stage
- Preclinical
- Lead developer
- Affibody
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
64Cu-NODAGA-ZHER2:S1 is an investigational radiopharmaceutical imaging agent designed for positron emission tomography (PET) to detect and quantify Human Epidermal Growth Factor Receptor 2 (HER2) expression in tumors. It consists of a HER2-targeting Affibody molecule (ZHER2:S1) conjugated to the triaza chelator NODAGA and labeled with the positron-emitting radioisotope Copper-64 (64Cu). Affibody molecules are small (approx. 7 kDa) engineered protein scaffolds derived from the B-domain of staphylococcal protein A, offering high affinity and specificity for their targets. 64Cu-NODAGA-ZHER2:S1 is primarily used for the non-invasive stratification of patients with HER2-positive cancers, such as breast cancer, to determine eligibility for HER2-targeted therapies. While it demonstrated strong targeting properties in early studies, it has served as a benchmark for developing next-generation tracers with optimized biodistribution, specifically aimed at reducing hepatic uptake.
- Other names
- Copper-64-NODAGA-ZHER2:S1[64Cu]Cu-NODAGA-ZHER2:S1
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on 64Cu-NODAGA-ZHER2:S1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 64Cu-NODAGA-ZHER2:S1.